Amphastar Pharmaceuticals vs Pacira Biosciences
Amphastar Pharmaceuticals and Pacira Biosciences are similar in size: $720m and $726m of revenue in their latest fiscal years. Pacira Biosciences grew faster (3.6% against -1.7%). Amphastar Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 13.6% against 1.0%. Pacira Biosciences carries less debt relative to equity (53.7% against 78.8%).
| Latest fiscal year | Amphastar PharmaceuticalsAMPH, 2025 | Pacira BiosciencesPCRX, 2025 |
|---|---|---|
| Revenue | $720m | $726m |
| Revenue growth | -1.7% | 3.6% |
| Net income | $98.1m | $7.0m |
| Operating margin | 19.5% | 2.6% |
| Net margin | 13.6% | 1.0% |
| Return on equity | 12.9% | 1.0% |
| Free cash flow | $121m | $137m |
| Cash | $170m | $159m |
| Total debt | $621m | $372m |
| Debt to equity | 78.8% | 53.7% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $75.6m | $148m |
| Employees | 1,976 | 829 |
| Market value | $1.15bn | $1.45bn |
| Price vs our value range | Below our value range | Below our value range |
| Moat score | 59 (Moderate) | 55 (Moderate) |
| Insider trades, 12 months | 0 buys, 11 sales | 0 buys, 17 sales |